New research suggests an intranasal vaccine may be effective in inducing immunity against COVID-19
Scientists have developed an intranasal COVID-19 vaccine that has been shown to deliver superior immunity than the current intramuscular vaccines.
The next-generation vaccine uses an adenoviral vector to deliver the trivalent vaccine that targets the spike protein, the nucleocapsid, and ribonucleic acid (RNA)-dependent RNA polymerase.
In a murine model, the single-dose intranasal vaccine was superior to intramuscular immunisation in inducing tripartite protective immunity consisting of local and systemic antibody responses, mucosal tissue-resident memory T cells, and mucosal trained innate immunity.
Intranasal immunisation provided protection against both the ancestral severe acute respiratory syndrome coronavirus-2 strain and two variants of concern, B.1.1.7 (Alpha) and B.1.351 (Beta).
The emerging variants of concern threaten the effectiveness of the current COVID-19 vaccines, which are administered intramuscularly and are designed to target only the spike protein. The authors of this study say ‘there is a pressing need to develop next-generation vaccine strategies for broader and long-lasting protection’.
Presenting the research in the journal Cell, the authors say: ‘Our findings indicate that respiratory mucosal delivery of ad-vectored multivalent vaccine represents an effective next-generation COVID-19 vaccine strategy to induce all-around mucosal immunity against current and future variants of concern.’
This article was originally published on Univadis, part of the Medscape Professional Network.
Lead image: Production Perig/stock.adobe.com
Image 1: Production Perig/stock.adobe.com